Reduxin - instructions for use, reviews, analogs and forms of release (tablets, capsules 10 and 15 mg, 625 mg) of the drug for weight loss, including during pregnancy. Differences Light form (without a prescription, dietary supplements). Side effects

In this article, you can read the instructions for using the drug Reduxin. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Reduxin in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues Reduxina in the presence of existing structural analogues. Use for the treatment of alimentary obesity and weight loss, including during pregnancy and lactation.

Reduxin - A combined drug for the treatment of obesity, the effect of which is due to its constituent components. Reduxin (its active substance Sibutramine) is a prodrug and shows its effect in vivo due to metabolites (primary and secondary amines) inhibiting the reuptake of monoamines (mainly serotonin and norepinephrine). An increase in the content of neurotransmitters in the synapses increases the activity of central serotonin 5-HT receptors and adrenoreceptors, which increases the feeling of satiety and reduced food requirements, as well as an increase in thermal production. By indirectly activating beta3-adrenoreceptors, Sibutramine acts on brown fatty tissue. The decrease in body weight is accompanied by an increase in the concentration in the blood serum of HDL and the decrease in the amount of triglycerides, total cholesterol, LDL, uric acid.

Redoxine and its metabolites do not affect the release of monoamines, do not inhibit MAO; have no affinity for a large number of neurotransmitter receptors, including serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C), adrenoreceptors (beta1, beta2, beta3, alpha1, alpha2), dopamine (D1, D2), muscarinic, histamine (H1), benzodiazepine and NMDA receptors.

Microcrystalline cellulose is an enterosorbent, it possesses sorption properties and nonspecific detoxification action. Binds and removes from the body various microorganisms, the products of their vital functions, toxins of exogenous and endogenous nature, allergens, xenobiotics, as well as an excess of certain metabolic products and metabolites responsible for the development of endogenous toxicosis.

Composition

Reduxin consists of two components:

• sibutramine hydrochloride monohydrate
• microcrystalline cellulose

Pharmacokinetics

After taking the drug inside, sibutramine is rapidly absorbed from the digestive tract, no less than 77%. Active metabolites undergo hydroxylation and conjugation with the formation of inactive metabolites, which are excreted mainly by the kidneys.

Indications

To reduce body weight with the following conditions:

• alimentary obesity with a body mass index (BMI) of 30 kg / m2 and more;
• nutritional obesity with a BMI of 27 kg / m2 or more in combination with other risk factors due to overweight (type 2 diabetes / non-insulin-independent / or dyslipoproteinemia).

Forms of release

The medicinal form in the form of tablets of the drug Reduxin does not exist. If you have met somewhere mention of tablets - do not believe it is a fake, which can be dangerous for your health.

Capsules 10 and 15 mg.

Reduxin Light - capsules 625 mg.

Instructions for use

Reduksin appointed inside once a day. The dose is set individually, depending on the tolerability and clinical effectiveness. The recommended initial dose is 10 mg, with poor tolerability, a dose of 5 mg is possible. Capsules should be taken in the morning without chewing and drinking with a sufficient amount of liquid. The drug can be taken as an empty stomach or combined with a meal.

If within 4 weeks from the beginning of treatment there is no reduction in body weight by 5% or more, then the dose is increased to 15 mg per day. The duration of therapy with Reduxin should not exceed 3 months in patients who do not respond well enough to therapy (ie, they can not reduce the weight by 5% of the initial body weight during the 3 months of treatment). Treatment should not be continued if, in further therapy (after the achieved weight loss), the patient again adds 3 kg or more in the body mass.

The total duration of therapy should not exceed 2 years, since there is no data on efficacy and safety for a longer period of sibutramine intake.

Therapy Reduxin should be conducted by a doctor who has a practical experience in the treatment of obesity. The intake of the drug should be combined with diet and exercise.

Differences Reduxina Light

Unlike the usual Reduxine Light form is a biologically active additive (BAD) and is sold in any pharmacy without a prescription.

Side effect

• dry mouth, insomnia;
• headache, dizziness;
• anxiety;
• paresthesia;
• depression;
• drowsiness;
• emotional lability, anxiety, irritability, nervousness;
• convulsions;
• tachycardia, palpitations;
• increased blood pressure;
• loss of appetite;
• constipation;
• nausea;
• sweating;
• itching;
• dysmenorrhea;
• edema;
• influenza-like syndrome;
• bleeding;
• thrombocytopenia.

Most often, side effects occur at the beginning of treatment (in the first 4 weeks). Their severity and frequency diminish over time. Side effects are generally light and reversible.

Contraindications

• the presence of organic causes of obesity (eg, hypothyroidism);
• serious eating disorders (anorexia nervosa or bulimia nervosa);
• mental illness;
• Gilles de la Tourette syndrome (generalized tics);
• simultaneous administration of MAO inhibitors (eg, phentermine, fenfluramine, dexfenfluramine, ethylamphetamine, ephedrine) or their use for 2 weeks prior to the administration of the drug Reduxine; the use of other drugs acting on the central nervous system (eg, antidepressants, antipsychotics); drugs prescribed for sleep disorders containing tryptophan, as well as other drugs of central action to reduce body weight;
• IHD, decompensated chronic heart failure, congenital heart diseases, occlusive diseases of peripheral arteries, tachycardia, arrhythmias, cerebrovascular diseases (stroke, transient disorders of cerebral circulation);
• uncontrolled arterial hypertension (blood pressure above 145/90 mm Hg);
• thyrotoxicosis;
• severe violations of liver function;
• severe renal dysfunction;
• benign prostatic hyperplasia;
• pheochromocytoma;
• angle-closure glaucoma;
• established drug, narcotic or alcohol dependence;
• pregnancy;
• lactation (breastfeeding);
• children and adolescents under 18;
• elderly age over 65;
• established hypersensitivity to sibutramine or to other components of the drug.

Application in pregnancy and lactation

The drug should not be used during pregnancy because of the lack of a sufficiently convincing number of studies of the safety of the effects of sibutramine on the fetus.

Women of childbearing age during the use of Reduxin should use contraceptives.

Reduxin should not be used during breastfeeding.

special instructions

Reduxin should be used only in those cases when all non-medicamentous measures to reduce body weight are ineffective - if the decrease in body weight during 3 months was less than 5 kg.

Treatment Reduxin should be carried out as part of a comprehensive therapy to reduce body weight under the supervision of a doctor who has practical experience in the treatment of obesity.

Complex therapy of obesity includes both changing diet and lifestyle, and increasing physical activity. An important component of therapy is the creation of prerequisites for a permanent change in eating habits and lifestyle that are necessary to maintain the achieved weight loss and after the abolition of drug therapy. Patients need to change their lifestyle and habits within the framework of therapy with the Reduxin drug in such a way as to ensure that the achieved weight loss is maintained after the treatment is completed. Patients should clearly realize that failure to comply with these requirements will lead to a second increase in body weight and repeated calls to the treating physician.

In patients taking Reduxin, it is necessary to measure blood pressure and heart rate. In the first 2 months of treatment, these parameters should be monitored every 2 weeks, and then monthly. In patients with hypertension (who have a blood pressure level above 145/90 mm Hg on the background of antihypertensive therapy), this control should be carried out especially carefully and, if necessary, at shorter intervals. In patients in whom blood pressure twice exceeded the level of 145/90 mm Hg on repeated measurement. treatment with Reduxin should be suspended.

The interval between taking MAO inhibitors and Reduxin should be at least 2 weeks.

The connection between the use of Reduction and the development of primary pulmonary hypertension has not been established, but considering the generally known risk of this group of drugs, with regular medical supervision, special attention should be paid to symptoms such as progressive dyspnea (breathing disorder), chest pain and swelling of the legs.

Impact on the ability to drive vehicles and manage mechanisms

The use of Reduxin can limit the patient's ability to drive and manage machinery.

Drug Interactions

Inhibitors of microsomal oxidation, incl. inhibitors of the 3A4 cytochrome P450 isoenzyme (including ketoconazole, erythromycin, cyclosporine) increase the plasma concentrations of sibutramine metabolites with an increase in heart rate and clinically insignificant increase in the QT interval. Rifampicin, macrolide antibiotics, phenytoin, carbamazepine, Phenobarbital and Dexamethasone can accelerate the metabolism of sibutramine. The simultaneous use of several drugs that increase serotonin levels in the blood can lead to the development of serious interaction.The so-called serotonin syndrome can develop in rare cases with the simultaneous use of Reduxin with selective serotonin reuptake inhibitors (drugs for the treatment of depression), with some drugs for the treatment of migraine (sumatriptan, dihydroergotamine), with potent analgesics (pentazocine, pethidine, fentanyl) or antitussive drugs (dextromethorphan). Sibutramine does not affect the effect of oral contraceptives.

With the simultaneous administration of sibutramine and ethanol (alcohol), there was no increase in the negative effect of ethanol. However, the use of alcohol is absolutely not compatible with the recommended dietary measures when taking sibutramine.

Analogs of the drug Reduxin

Structural analogs for the active substance:

• Reduxin Light

Similar medicines:

Other medicines: